Authors/Disclosures
|
Kiyokazu Kawabe, MD
(Department of Neurology Saiseikai Yokohamashi Tobu Hospital)
|
No disclosure on file |
|
Yasuhiro Yoshii, MD, PhD
(Nippon-Koukan Hospital)
|
No disclosure on file |
|
Osamu Kano, MD, PhD
(Department of Neurology, Toho University Faculty of Medicine)
|
Dr. Kano has nothing to disclose. |
|
Ken Ikeda, MD, PhD
(Toho University Omori Medical Center)
|
No disclosure on file |
|
Yasuo Iwasaki, MD
|
No disclosure on file |
|
Stephen L. Hauser, MD
(UCSF Weill Institute for Neurosciences)
|
Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NGM Bio. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BD. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pheno Therapeutics. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nurix Therapeutics. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gilead. Dr. Hauser has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Accure. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hinge Therapeutics. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Neurona. Dr. Hauser has a non-compensated relationship as a Clinical Trial/Primary Investigator with Roche that is relevant to AAN interests or activities. Dr. Hauser has a non-compensated relationship as a Clinical Trial/Primary Investigator with Novartis that is relevant to AAN interests or activities. |